CD19 and acute lymphoblastic leukemia: Commissioned by the American Society for Blood and Marrow Transplant (ASBMT) Practice Guidelines Committee and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT), a global CAR-T Task Force was developed to help identify and address the key challenges in the treatment and management of patients with relapsed or refractory B-ALL destined to undergo treatment with anti CD19 CAR-T such as tisagenlecleucel.